China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Apple Turns 50: From Garage Startup to AI Crossroads 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Britain Courts Anthropic Amid US Defense Department Dispute 
SAN RAMON, Calif., Sept. 09, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. The presentation will take place on Tuesday, September 13, 2016 at 5:05 p.m. ET at The Lotte New York Palace Hotel, in New York, NY.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 [email protected]
